STOPFOP site Klinikum Garmisch-Partenkirchen is now open for inclusions
The STOPFOP team is pleased to announce that ‘The Saracatinib trial to prevent Fibrodysplasia Ossificans Progressiva’ (STOPFOP) has opened the study site in Garmish-Partenkirchen.
Due to the COVID-19 pandemic the start of the study was delayed in Garmisch-Partenkirchen. Hospitals and authorities were being fully dedicated to fighting the outbreak. Now, with additional precautions, the study can once again help research into FOP drugs forward. “We have put measures into place to make sure that visits to our centers will be conducted in a clean and safe environment”, said Marelise Eekhoff, coordinating investigator for the trial ealier.
The local STOPFOP team in Garmisch-Partenkirchen is led by dr. Clemens Stockklausner who reported: ”I am very glad that we will finally be able to help patients with FOP with a second centre for this trial". He is supported by, amongst others, by Lena Waeckerle and Birgitt Nebel. Names that many FOP patients will recognize as the Klinikum Garmisch-Partenkirchen has a long history of expertise in FOP.
Patients or caregivers who wish to learn more about this trial, or to contact the researchers, can find more information at the website www.stopfop.com.